Science: Low-dose Moderna Covid-19 vaccine can trigger a long-lasting immune response

In a new study, researchers from the La Jolla Institute of Immunology (LJI) in the United States helped answer the question: How long can the vaccinated person's immunity to COVID-19 last? They report that the immunity produced by the low-dose Moderna mRNA-1273 new crown vaccine can last at least six months, and there is no sign that vaccinators need booster injections

In fact, although the Moderna mRNA-1273 new crown vaccine caused a strong CD4+ (helper) T cell, CD8+ (killer) T cell and antibody response at least 6 months after the clinical trial participants were fully vaccinated, this immunity The reaction is likely to last longer

Compare Moderna vaccine to natural immunity

The authors compared recovered COVID-19 patients with trial participants who received a dose of 25 micrograms of Moderna's new crown vaccine during the phase 1 clinical trial

This vaccine dose is one-fourth of the 100 micrograms Moderna new crown vaccine authorized by the U.

Transmission electron microscope images of SARS-CoV-2, a novel coronavirus infection (coronavirus that causes COVID-19) isolated from American patients, showed that virus particles appeared on the surface of cells cultured in the laboratory

In fact, these authors found that Moderna's new crown vaccine stimulated an adaptive immune response to the SARS-CoV-2 spike protein (a key target), almost the same as the immune system's response to SARS-CoV-2 natural infection

This new study does not show that the lower dose of Moderna's new crown vaccine provides the same protection as the standard dose

The common cold coronavirus does prepare the immune system

This new study also shows the power of "cross-reactive" T cells

For this new study, these authors found that people with cross-reactive T cells had significantly stronger CD4+ T cell and antibody responses to both doses of Moderna's new crown vaccine

Moderna's new crown vaccine activates "killer" T cells

The team also filled an important gap in COVID-19 vaccine research

Sette said that the new study showed a strong CD8+ T cell response to the low-dose Moderna Covid-19 vaccine, similar to the response of patients to natural SARS-CoV-2 infection

Next, Weiskopf and her colleagues are investigating whether this vaccine persistence also applies to other types of COVID-19 vaccines? At the same time, Weiskopf said, real-world data show that immune memory can indeed be sustained

Note: The original text has been deleted

Reference materials:

Jose Mateus et al.